All News
Night Splinting for Carpal Tunnel (3.24.2023)
Dr. Jack Cush reviews the news and journal articles from the past 2 weeks on RheumNow.com. This week reviews clinical associations with SS-A, a new biomarker for SSc-ILD and cancer screening for myositis patients.
Read Article
Anti-mesangial autoantibodies in IgA nephropathy
d
EurekAlert!
IgA nephropathy (IgAN) is a kidney disorder characterized by the buildup of immunoglobin A (IgA) in the glomeruli, which are bundles of capillaries that filter blood in the kidney.
Read Article
Tofacitinib May Reduce Interstitial Lung Disease Risk in RA
d
MedPage Today
Tofacitinib (Xeljanz) in patients with rheumatoid arthritis (RA) stood out among several other biologic and targeted synthetic disease-modifying antirheumatic drugs (sDMARDs) when it came to the incidence of interstitial lung disease (ILD), a retrospective cohort study showed.
Read Article
What to do about pre-clinical RA?
Much like the recent ACR Convergence, RheumNow Live’s 2023 conference led with this year’s hot topic of rheumatoid arthritis and especially what to do regarding pre-clinical RA.
https://t.co/k8LcTmlpZs https://t.co/NBBbi91Fbi
Links:
Dr. John Cush RheumNow ( View Tweet)
Our old friend, hydroxychloroquine
Dr.Arnaud ( @Lupusreference ) took the time to review one of our oldest therapies: hydroxychloroquine. He outlined how the anti-malarial medication has efficacy and widespread usage in lupus.
https://t.co/NJK7uJIqsV https://t.co/CQStRUUkUn
Links:
Dr. John Cush RheumNow ( View Tweet)
#RNL2023
Dr. Stanley Cohen: possible adverse effects of JAKi
-Herpes zoster, other infections
-Malignancy
-Occasional cytopenias
-LFTs (with DMARDs)
-Incr Cr or CPK
-Acne
-Incr lipids
-GI perf
-VTE
Which do you counsel with your patients? https://t.co/Ej0Rm2VFCk https://t.co/aiHGE1LsAr
Links:
Dr. John Cush RheumNow ( View Tweet)
#RNL2023:Kevin Deane: Anti-CCP positive leads to a 20-30% risk for articular clinical RA within 3-5 years https://t.co/UvXfC2iIEp https://t.co/zBoMiyy056
Links:
Dr. John Cush RheumNow ( View Tweet)
EULAR has published the 2022 update on recommendations for the management of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). https://t.co/0fXUVv0sCR https://t.co/fT6iAOPOpc
Links:
Dr. John Cush RheumNow ( View Tweet)
LRA announces the 2023 recipients of the Lupus Innovation Award during #NationalKidneyMonth as three of this year’s seven award recipients are studying issues that come with this too-common complication.
🧵1of2 https://t.co/VZL9qJu9kF
Lupus Research LupusResearch ( View Tweet)
Updated AAV Treatment Recommendations
AAV is a multi-organ disease, which can be complex and may vary from person to person. Types of AAV include GPA, microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA).
https://t.co/YCNGYZfSr1 https://t.co/MFs9ykm4fb
Links:
Dr. John Cush RheumNow ( View Tweet)
Our old friend, hydroxychloroquine
Dr.Arnaud ( @Lupusreference ) took the time to review one of our oldest therapies: hydroxychloroquine. He outlined how the anti-malarial medication has efficacy and widespread usage in lupus.
https://t.co/hKFLg1sogJ https://t.co/OxnbwpWygF
Links:
Dr. John Cush RheumNow ( View Tweet)
#RNL2023
Dr. Stanley Cohen: possible adverse effects of JAKi
-Herpes zoster, other infections
-Malignancy
-Occasional cytopenias
-LFTs (with DMARDs)
-Incr Cr or CPK
-Acne
-Incr lipids
-GI perf
-VTE
Which do you counsel with your patients? https://t.co/8bEEC6gt5Z https://t.co/Toy2DxnC4S
Links:
Dr. John Cush RheumNow ( View Tweet)
Treat to target approach in PsA
Systematic rev: 12-43% pts achieved target of very low disease activity or remission
Pts and docs agree: remission is primary goal, but Low disease activity is acceptable alternative
@DrLauraCoates at #RNL2023
https://t.co/XyXBAn82F1 https://t.co/W0nVdq6urq
Links:
Dr. John Cush RheumNow ( View Tweet)
#RNL2023: Kevin Deane: Anti-CCP positive leads to a 20-30% risk for articular clinical RA within 3-5 years
@RheumNow https://t.co/vPflDm22b2 https://t.co/7Al9I3Eidu
Links:
Dr. John Cush RheumNow ( View Tweet)
Retrospective study of Apremilast survival in 281 #psoriasis pts(22% w/ PsA) showed 1 yr drug survival=54%, less at 2 yrs (41%), 3 yrs (32%), and 4 yrs (30%). Half 1+ adverse events; D/C mostly for lack of efficacy (27%), adverse events (12%) https://t.co/2dm6H6cYNX https://t.co/F2YtzzWMdT
Links:
Dr. John Cush RheumNow ( View Tweet)
Phase 3 trial of IV 200 mg qd hydrocortisone in 800 pts admitted to ICU for severe community-acquired pneumonia. Day 28 strongly favored IV Hydrocort vs PBO for mortality (6% v 12%; P=0.006), Mech ventilation (18% vs 29.5%), vasopressors (15% v 25%) https://t.co/TqxorRAuvc https://t.co/0R7kNaKgj5
Links:
Dr. John Cush RheumNow ( View Tweet)
#RNL2023:Kevin Deane: Anti-CCP positive leads to a 20-30% risk for articular clinical RA within 3-5 years https://t.co/MZJfg2lM70 https://t.co/eOkcwd4xMz
Links:
Dr. John Cush RheumNow ( View Tweet)
The Biosimilar "Buy In"
Dr. Rachel Tate, @uptotate , shared insights into these key discussions during RheumNow Live.
https://t.co/dD3uZCNQEo https://t.co/MuN91Oqbvo
Links:
Dr. John Cush RheumNow ( View Tweet)
Metformin Reduces Osteoarthritis Risk
Metformin may help cut the risk of osteoarthritis (OA) in those with type 2 diabetes, researchers reported.
https://t.co/dmyKssbWjO https://t.co/p7lPdjYfbU
Links:
Dr. John Cush RheumNow ( View Tweet)
Spondyloarthritis Innovations
The second day of RheumNow Live 2023 ended with a focus on axial spondyloarthritis, especially on the evaluation of the definition of the disease, the inheritance of it, and of course the treatment of it.
https://t.co/3JeNeE0EO6 https://t.co/fA1B2TA2xF
Links:
Dr. John Cush RheumNow ( View Tweet)